Elicio Therapeutics, Inc. Earnings Per Share (Basic)
Elicio Therapeutics, Inc. (ELTX) reported Earnings Per Share (Basic) of -$0.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Elicio Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.43.
- Elicio Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.65.
- Elicio Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.50.
- Elicio Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.60.
- Elicio Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.58.
- Elicio Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$4.25.
- Elicio Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$6.96.
- Elicio Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$89.27.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.43 10-Q · filed 2026-08-13 | -$1.07 10-Q · filed 2026-08-13 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.65 10-Q · filed 2026-05-11 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.58 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$0.60 10-Q · filed 2025-11-13 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.09 10-Q · filed 2025-11-13 | -$3.09 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$0.66 10-Q · filed 2026-08-13 | -$1.50 10-Q · filed 2026-08-13 | -$2.52 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.88 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$0.87 10-Q · filed 2026-05-11 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.29 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.99 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2024-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$3.12 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$4.25 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$1.39 10-Q · filed 2025-11-13 | -$2.10 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$3.23 10-Q · filed 2025-11-13 | -$4.29 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-06-30 | -$0.64 10-Q · filed 2025-08-07 | -$1.77 10-Q · filed 2025-08-07 | -$2.79 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$4.02 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-03-31 | -$1.15 10-Q · filed 2025-05-13 | -$2.21 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$3.47 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$5.18 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2023-12-31 | -$1.05 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$2.32 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$4.11 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$6.96 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$1.27 10-Q · filed 2024-11-13 | -$3.23 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$6.75 10-Q · filed 2024-11-13 | -$3.19 10-Q · filed 2023-11-13 | -$11.04 derived: net income ÷ weighted average shares · filed 2024-11-13 | |||
| 2023-06-30 | -$2.61 10-Q · filed 2024-08-13 | -$2.44 10-Q · filed 2023-08-14 | -$9.65 10-Q · filed 2024-08-13 | -$9.06 10-Q · filed 2023-08-14 | -$18.86 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$30.54 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-03-31 | -$24.77 10-Q · filed 2024-05-15 | -$0.15 10-Q · filed 2023-05-10 | -$45.57 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$68.24 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$91.44 derived: net income ÷ weighted average shares · filed 2024-11-13 | |||
| 2022-12-31 | -$20.78 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$43.44 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$66.63 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$89.27 10-K · filed 2024-03-29 | -$1.29 10-K · filed 2023-03-17 | |||
| 2022-09-30 | -$22.67 10-Q · filed 2023-11-13 | -$0.30 10-Q · filed 2022-11-14 | -$45.87 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$68.52 10-Q · filed 2023-11-13 | -$1.08 10-Q · filed 2022-11-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||
| 2022-06-30 | -$23.20 10-Q · filed 2023-08-14 | -$0.30 10-Q · filed 2022-08-15 | -$45.85 10-Q · filed 2023-08-14 | -$0.78 10-Q · filed 2022-08-15 | $0.03 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.67 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||
| 2022-03-31 | -$0.48 10-Q · filed 2023-05-10 | $0.26 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.84 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2021-12-31 | $0.50 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$0.03 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$1.93 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$0.53 10-Q · filed 2022-11-14 | -$1.10 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.51 10-Q · filed 2022-11-14 | -$4.01 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2021-06-30 | -$0.58 10-Q · filed 2022-08-15 | -$2.02 10-Q · filed 2022-08-15 | -$3.63 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$4.82 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2021-03-31 | -$1.56 10-Q · filed 2022-05-16 | -$3.39 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$4.67 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$6.09 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||||
| 2020-12-31 | -$1.90 derived: net income ÷ weighted average shares · filed 2022-03-30 | -$3.10 derived: net income ÷ weighted average shares · filed 2022-03-30 | -$4.50 derived: net income ÷ weighted average shares · filed 2022-03-30 | -$5.43 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | -$1.19 10-Q · filed 2021-11-12 | -$2.59 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$3.51 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$1.40 10-Q · filed 2021-08-12 | -$2.32 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$0.91 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |